Therapeutic Asset Ratings

6,371 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Pembrolizumab Radiotherapy	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P4	B (63)
Pembrolizumab Surgery Programmed	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P4	B (63)
Relatlimab Melanoma	Bristol-Myers Squibb	P4	B (63)
Toripalimab Breast Cancer	Zhejiang Cancer Hospital	P4	B (63)
Amivantamab-Vmjw Non-Small Cell Lung Carcinoma	Janssen Research & Development, LLC	P3	B (63)
Botensilimab Colorectal Cancer	National Cancer Institute (NCI)	P3	B (63)
Cetuximab Capecitabine	Meng Qiu	P3	B (63)
Cetuximab Cetuximab	Tianjin Medical University Cancer Institute and Hospital	P3	B (63)
Cetuximab Metastatic Malignant Neoplasm	Revolution Medicines, Inc.	P3	B (63)
Durvalumab Bladder Transitional Cell Carcinoma	Alliance for Clinical Trials in Oncology	P3	B (63)
Durvalumab Hormone Receptor-Positive Breast Cancer	National Cancer Institute (NCI)	P3	B (63)
Durvalumab Papillary Renal Cell Carcinoma	AstraZeneca	P3	B (63)
IMMUNOGLOBULIN G1, ANTI-(HUMAN 5'-NUCLEOTIDASE) (HUMAN MONOCLONAL MEDI9447 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL MEDI9447 .LAMBDA.-CHAIN, DIMER Non-Small Cell Lung Carcinoma	Montefiore Medical Center	P3	B (63)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Anemia	OHSU Knight Cancer Institute	P3	B (63)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER B-Cell Acute Lymphoblastic Leukemia	University of Washington	P3	B (63)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Large B-Cell Lymphoma	Ruijin Hospital	P3	B (63)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Nervous System Disorder	Amsterdam UMC, location VUmc	P3	B (63)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Primary Progressive Multiple Sclerosis	Rigshospitalet, Denmark	P3	B (63)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Sun Yat-sen University	P3	B (63)
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER Small Cell Lung Carcinoma	Alliance Foundation Trials, LLC.	P3	B (63)
Ipilimumab Glioblastoma	University College, London	P3	B (63)
Ipilimumab Hepatocellular Carcinoma	University of Hawaii	P3	B (63)
Nivolumab Colorectal Cancer	Fred Hutchinson Cancer Center	P3	B (63)
Nivolumab Glioblastoma	Duke University	P3	B (63)
Obinutuzumab Carcinoma, Non-Small-Cell Lung	NeoTX Therapeutics Ltd.	P3	B (63)

Showing 576 to 600 of 6,371 assets

PreviousPage 24 of 255Next